A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003)

Clinical Trial ID NCT01304524

Rank	Title	Journal	Year	PubWeight™‹?›
1	Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.	Lancet	2015	2.69
2	Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.	Sci Transl Med	2014	1.21
3	Trial watch: DNA vaccines for cancer therapy.	Oncoimmunology	2013	1.11
4	Emerging human papillomavirus vaccines.	Expert Opin Emerg Drugs	2012	0.96
5	Immunologic treatments for precancerous lesions and uterine cervical cancer.	J Exp Clin Cancer Res	2014	0.96
6	Therapeutic Vaccine Strategies against Human Papillomavirus.	Vaccines (Basel)	2014	0.89
7	Trial Watch: DNA vaccines for cancer therapy.	Oncoimmunology	2014	0.86
8	Preclinical and clinical development of DNA vaccines for prostate cancer.	Urol Oncol	2013	0.86
9	Trial watch: Naked and vectored DNA-based anticancer vaccines.	Oncoimmunology	2015	0.83
10	Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.	Curr Obstet Gynecol Rep	2014	0.79
11	Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors.	Gene Ther	2015	0.79
12	Immunotherapy for head and neck cancer: latest developments and clinical potential.	Ther Adv Med Oncol	2016	0.75